ORPHA:645626
Adermatopathic dermatomyositis
Also known as: Dermatomyositis sine dermatitis
Publications
55
50.8th percentile
Trials
0
Interventional, condition-specific
Researchers
259
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0957458
- UMLS:C5816708
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
55 matched papers (43 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 123 for broader category dermatomyositis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
55
55 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
55 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
43 in the last 10 years · high confidence · 50.8th percentile (publications denominator)
Phrase hits: 55 · MeSH hits: 0
Who's working on it?
259
Distinct author names in 55 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Nishino I8 papers · 2026
From the Department of Neuromuscular Research, National Institute of Neuroscience (J.T., M.I., Y.S., S.H., S.N., I.N.), Department of Genome Medicine Development, Medical Genome Center (J.T., M.I., Y.S., S.H., S.N., I.N.), and Department of Clinical Epidemiology, Translational Medical Center (H.T.), National Center of Neurology and Psychiatry (NCNP); Endowed Course for Health System Innovation (H.T.), Keio University School of Medicine, Tokyo; Department of Dermatology, Faculty of Medicine (N.O.), University of Tsukuba, Ibaraki; and Department of Dermatology (M.F.), Graduate School of Medicine, Osaka University, Japan. nishino@ncnp.go.jp.
Papers in Europe PMC - 02Okiyama N6 papers · 2024
From the Department of Neuromuscular Research, National Institute of Neuroscience (J.T., M.I., Y.S., S.H., S.N., I.N.), Department of Genome Medicine Development, Medical Genome Center (J.T., M.I., Y.S., S.H., S.N., I.N.), and Department of Clinical Epidemiology, Translational Medical Center (H.T.), National Center of Neurology and Psychiatry (NCNP); Endowed Course for Health System Innovation (H.T.), Keio University School of Medicine, Tokyo; Department of Dermatology, Faculty of Medicine (N.O.), University of Tsukuba, Ibaraki; and Department of Dermatology (M.F.), Graduate School of Medicine, Osaka University, Japan.
Papers in Europe PMC - 03Tanboon J5 papers · 2022
From the Department of Neuromuscular Research, National Institute of Neuroscience (J.T., M.I., Y.S., S.H., S.N., I.N.), Department of Genome Medicine Development, Medical Genome Center (J.T., M.I., Y.S., S.H., S.N., I.N.), and Department of Clinical Epidemiology, Translational Medical Center (H.T.), National Center of Neurology and Psychiatry (NCNP); Endowed Course for Health System Innovation (H.T.), Keio University School of Medicine, Tokyo; Department of Dermatology, Faculty of Medicine (N.O.), University of Tsukuba, Ibaraki; and Department of Dermatology (M.F.), Graduate School of Medicine, Osaka University, Japan.
Papers in Europe PMC - 04Fujimoto M4 papers · 2022
From the Department of Neuromuscular Research, National Institute of Neuroscience (J.T., M.I., Y.S., S.H., S.N., I.N.), Department of Genome Medicine Development, Medical Genome Center (J.T., M.I., Y.S., S.H., S.N., I.N.), and Department of Clinical Epidemiology, Translational Medical Center (H.T.), National Center of Neurology and Psychiatry (NCNP); Endowed Course for Health System Innovation (H.T.), Keio University School of Medicine, Tokyo; Department of Dermatology, Faculty of Medicine (N.O.), University of Tsukuba, Ibaraki; and Department of Dermatology (M.F.), Graduate School of Medicine, Osaka University, Japan.
Papers in Europe PMC - 05Inoue M4 papers · 2022
From the Department of Neuromuscular Research, National Institute of Neuroscience (J.T., M.I., Y.S., S.H., S.N., I.N.), Department of Genome Medicine Development, Medical Genome Center (J.T., M.I., Y.S., S.H., S.N., I.N.), and Department of Clinical Epidemiology, Translational Medical Center (H.T.), National Center of Neurology and Psychiatry (NCNP); Endowed Course for Health System Innovation (H.T.), Keio University School of Medicine, Tokyo; Department of Dermatology, Faculty of Medicine (N.O.), University of Tsukuba, Ibaraki; and Department of Dermatology (M.F.), Graduate School of Medicine, Osaka University, Japan.
Papers in Europe PMC - 06
- 07Nilipour Y3 papers · 2020
Pediatric Pathology Research Center, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Papers in Europe PMC - 08Chinoy H2 papers · 2019
NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK and Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK.
Papers in Europe PMC - 09Danielsson O2 papers · 2020
Division of Neurology, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Papers in Europe PMC - 10Ernerudh J2 papers · 2020
Division of Clinical Immunology and Transfusion Medicine, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 123 trials are registered for dermatomyositis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
123 interventional trials matched dermatomyositis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: dermatomyositis
123
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06686524·RECRUITING·Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)
Conditions: Dermatomyositis, Juvenile · Dermatomyositis·Matched via name phrase
- NCT07349667·NOT YET RECRUITING·Hypnotherapy for Needle-related Procedural Pain and Anxiety Management in a Pediatric Setting
Conditions: Arthritis, Juvenile · Arthritis, Juvenile Idiopathic · Lupus Erythematosus, Systemic · Dermatomyositis, Juvenile·Matched via name phrase
- NCT06371417·RECRUITING·Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Conditions: Antiphospholipid Syndrome (APS) · Bullous Pemphigoid (BP) · Behçet's Syndrome (BS) · Dermatomyositis (DM)·Matched via name phrase
- NCT03582800·RECRUITING·Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study
Conditions: Systemic Sclerosis · Dermatomyositis · iPPSD2·Matched via name phrase
- NCT05495321·ENROLLING BY INVITATION·Interleukin-2 on Active Dermatomyositis
Conditions: Dermatomyositis·Matched via name phrase
- NCT07160205·RECRUITING·Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)
Conditions: Idiopathic Inflammatory Myositis (IIM) · DERMATOMYOSITIS OR POLYMYOSITIS·Matched via name phrase
- NCT07184450·RECRUITING·Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
Conditions: Juvenile Dermatomyositis (JDM) · Polyarticular Juvenile Idiopathic Arthritis · Systemic Sclerosis (SSc) · Primary Sjogren's Syndrome·Matched via name phrase
- NCT04972760·RECRUITING·Baricitinib in Patients With Relapsing or naïve Dermatomyositis
Conditions: Dermatomyositis·Matched via name phrase
- NCT06857240·RECRUITING·Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
Conditions: Dermatomyositis·Matched via name phrase
- NCT06568783·NOT YET RECRUITING·Evaluation of Patients With Refractory Dermatomyositis Using [18F] FAPI-74 PET/MRI Imaging
Conditions: Refractory Dermatomyostitis·Matched via name phrase
- NCT05895786·RECRUITING·A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Conditions: Myositis·Matched via name phrase
- NCT05979441·ENROLLING BY INVITATION·A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Conditions: Myositis · Active Idiopathic Inflammatory Myopathy · Dermatomyositis · Polymyositis·Matched via name phrase
- NCT06154252·RECRUITING·RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Conditions: Idiopathic Inflammatory Myopathy · Dermatomyositis · Anti-Synthetase Syndrome · Immune-Mediated Necrotizing Myopathy·Matched via name phrase
- NCT06685042·RECRUITING·Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
Conditions: Lupus Erythematosus, Systemic · System; Sclerosis · ANCA Associated Vasculitis · Dermatomyositis·Matched via name phrase
- NCT06298019·RECRUITING·Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
Conditions: Dermatomyositis·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Adermatopathic dermatomyositis" OR "Dermatomyositis sine dermatitis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Adermatopathic dermatomyositis" OR "Dermatomyositis sine dermatitis"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"dermatomyositis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T19:42:45.413Z
